Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Radiation Toxicity

Sun Yat-sen UniversitySmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Radiation Toxicity cohort.

Asset / SponsorPhaseRating
FILGRASTIM
IRCCS San Raffaele
Phase 3BB
Amifostine
Alliance for Clinical Trials in Oncology
Phase 3BB
ETOPOSIDE
Sun Yat-sen University
Phase 3BB
Carboplatin
Sun Yat-sen University
Phase 3BB
Mometasone
North Central Cancer Treatment Group
Phase 3B

View all 37 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →